RxDoctor Payments Data

Veena Vangani, MD

Internal Medicine · Fredericksburg, VANPI 1508838731

Payments from drug & device makers

$9,950in general payments, 2019–2025

Across 584 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$843
  • Amgen$828
  • GSK$494
  • Boehringer Ingelheim$452
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$9,83499%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)131$1,802
Novo Nordisk84$1,481
Pfizer59$843
Amgen(2 entities)48$828
GSK24$494
Boehringer Ingelheim21$452
Lilly USA, LLC21$416
AstraZeneca(2 entities)17$345
Bayer18$307
Astellas Pharma US Inc9$261
Abbott11$235
Novartis12$228
Esperion Therapeutics, Inc.15$226
Merck13$191
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$148
E.r. Squibb & Sons, L.L.C.5$116
Takeda Pharmaceuticals U.S.A., Inc.6$111
Otsuka America Pharmaceutical, Inc.6$101
Exact Sciences5$101
Biohaven Pharmaceutical Holding Company Ltd.4$78
Sunovion Pharmaceuticals Inc.4$77
Eisai Inc.4$75
Actelion Pharmaceuticals US, Inc.3$54
Dynavax Technologies Corporation3$45
Supernus Pharmaceuticals, Inc.3$44
Biogen2$41
Johnson & Johnson3$39
Teva Pharmaceuticals USA, Inc.3$39
Axsome Therapeutics, Inc.2$37
Boston Scientific2$36
Lundbeck LLC2$36
Ultragenyx Pharmaceutical Inc.2$33
Sanofi-aventis U.S. LLC2$32
Medtronic2$31
Ardelyx, Inc.2$29
Neurelis, Inc.2$28
Vanda Pharmaceuticals Inc.1$26
Sumitomo Pharma America, Inc.1$25
Aimmune Therapeutics, Inc.1$25
UCB, Inc.1$24
Daiichi Sankyo Inc.1$24
Dexcom, Inc.1$23
Jazz Pharmaceuticals Inc.1$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$23
Cranial Technologies, Inc1$22
Bardy Diagnostics, Inc.1$21
SK Life Science, Inc.1$20
Hologic Sales And Service, LLC1$20
Verona Pharma, Inc.1$19
Idorsia Pharmaceuticals US Inc1$19
Azurity Pharmaceuticals, Inc.1$19
Edwards Lifesciences1$19
Sanofi Pasteur Inc.1$18
Amarin Pharma, Inc.1$18
Vyera Pharmaceuticals, LLC1$18
Viatris Specialty LLC1$17
Averitas Pharma Inc.1$17
Regeneron Healthcare Solutions, Inc.1$16
Phathom Pharmaceuticals, Inc.1$14
Watermark Medical, Inc.1$14

How this compares

$9,950 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$309,041
Medicare patients
887
Services billed
5,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$110,847
JardianceEmpagliflozin90$107,867
TrulicityDulaglutide76$101,705
MounjaroTirzepatide84$89,849
EliquisApixaban82$68,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$61,910
JanuviaSitagliptin Phosphate59$59,942
FarxigaDapagliflozin Propanediol50$54,305
Repatha SureclickEvolocumab48$36,653
RexultiBrexpiprazole22$31,135
XareltoRivaroxaban27$31,038
LinzessLinaclotide44$30,735
CreonLipase/Protease/Amylase12$13,695
Tresiba Flextouch U-100Insulin Degludec22$13,330
NexletolBempedoic Acid20$13,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$416$191,554160 claims
Novo NordiskOzempic$1,481$110,84797 claims
Boehringer IngelheimJardiance$452$107,86790 claims
MerckJanuvia, Janumet Xr$191$72,00075 claims
GSKTrelegy Ellipta, Breo Ellipta$494$69,51279 claims
PfizerEliquis$843$68,75682 claims
AstraZenecaFarxiga, Symbicort$345$59,93866 claims
AbbVieLinzess, Creon, Synthroid$1,802$47,813125 claims
Otsuka America Pharmaceutical, Inc.Rexulti$101$31,13522 claims
Johnson & JohnsonXarelto$39$31,03827 claims
Esperion Therapeutics, Inc.Nexletol$226$13,29520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →